Free Trial

scPharmaceuticals Q2 2023 Earnings Report

scPharmaceuticals logo
$3.32 +0.07 (+2.15%)
(As of 10:50 AM ET)

scPharmaceuticals EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.37
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

scPharmaceuticals Revenue Results

Actual Revenue
$1.64 million
Expected Revenue
$1.55 million
Beat/Miss
Beat by +$90.00 thousand
YoY Revenue Growth
N/A

scPharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

"X-Ray Vision" could find thousands of hidden market opportunities (Ad)

Let me show you how I trade with “X-Ray vision.” You see, most “trend” traders only use one trend filter when looking for an optimal buy signal. And that can be a big mistake because you can’t see if you’re in a “True Trend.” But my newest trading tool is designed to only target the best, most stable stocks… Using 3 trend filters… which are these green, yellow, and red lines.

Just tap here to join the presentation.

scPharmaceuticals Earnings Headlines

TD Cowen Sticks to Its Buy Rating for scPharmaceuticals (SCPH)
Craig-Hallum Issues a Buy Rating on scPharmaceuticals (SCPH)
Could this be the hottest crypto discovery of all time?
I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free…
See More scPharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like scPharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on scPharmaceuticals and other key companies, straight to your email.

About scPharmaceuticals

scPharmaceuticals (NASDAQ:SCPH), a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

View scPharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings